Positron - POSC STOCK NEWS

Positron (OTC: POSC) has secured exclusive North American rights to sell and distribute the NeuSight PET-CT 64 slice scanner through an agreement with Shenyang Intelligent Nuclear Medical Technology Co., a subsidiary of Neusoft Medical Systems. This award-winning scanner has FDA clearance for the US market and will be introduced in July 2024 for nuclear cardiac imaging. NeuSight PET-CT 64 offers advanced imaging for heart, tumor, and brain studies, combining anatomical and functional imaging with improved speed and accuracy. Positron aims to meet the increasing demand in the US, Canada, and Mexico, leveraging the system’s international success, with around 500 units sold globally.

Positron (OTC: POSC) has entered an agreement to acquire the FDA 510(k) clearance for the NeuSight PET-CT from Neusoft Medical Systems' subsidiary. This acquisition enables Positron to immediately market and sell the NeuSight PET-CT 64 slice imaging system and facilitates future FDA clearances for their Affinity PET-CT 4D 64 slice system. Adel Abdullah, President of Positron, emphasized that this milestone will significantly enhance their product line, which is vital for both oncology and nuclear cardiology. Positron aims to offer advanced PET-CT technology to healthcare practices, supported by Neusoft's extensive R&D expertise.

Positron Corporation (POSC) welcomes a prominent cardiovascular practice in Pennsylvania as a new customer utilizing the Attrius PET System and services. The company offers a dedicated PET scanner optimized for nuclear cardiology, providing robust high-resolution images and accurate measurements of absolute blood flow. Positron's Lease to Own Program offers a complete package of the Attrius PET System and full scope Clinical & Technical Services for one monthly price for five years, with zero upfront capex expense. The company expects to enter additional lease to own/services agreements with other interested parties.

Positron welcomes a prominent cardiovascular practice in California as a new customer utilizing Positron's Attrius PET System and services. The company anticipates entering five more Attrius Lease to Own/Services agreements by year's end. Positron's PET Lease to Own & Services Program offers a complete package with zero upfront capex expense, providing a viable operational model for nuclear imaging PET practices. The company aims to provide hospitals and private practices with the best technology, services, and solutions to meet customer needs.

Positron Corporation to begin clinical study of Affinity PET-CT imaging device with Ochsner Clinic Foundation

Positron Corporation (POSC) Announces Business Cooperative Partnership and Acquisition of PET Imaging Systems Inventory

Positron Corporation (OTC: POSC) has entered a Clinical Study/Research Agreement with Ochsner Clinic Foundation for its new Affinity™ PET-CT 4D device. This agreement facilitates the collection of safety and efficacy data, crucial for obtaining an Investigational Device Exemption (IDE) from the FDA. The independent Institutional Review Board has approved all study procedures, allowing preparations for patient scans to begin post-IDE approval. The company aims for completion of the clinical study and FDA certification within 60 days, marking a significant step toward commercialization.

Positron Corporation (OTC: POSC) announces a collaboration with Dr. Robert Bober and Ochsner Health for a clinical study of its new Affinity PET-CT 4D imaging device. This FDA-compliant study, commencing mid-January 2023, aims to evaluate the device's image quality and performance in cardiac PET imaging. Dr. Bober's leadership is pivotal for gathering empirical data essential for marketing the system. Following completion and FDA 510k certification, Positron intends to commercialize the device in Q1 2023, targeting nuclear cardiology and oncology markets.